Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.

Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK.

J Clin Pharmacol. 2019 Sep 12. doi: 10.1002/jcph.1524. [Epub ahead of print]

PMID:
31515816
2.

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.

Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C, Hierro L, Kelly D, Ling SC, Strokova T, Del Valle-Segarra A, Lovell S, Liu W, Ng TI, Porcalla A, Gonzalez YS, Burroughs M, Sokal E.

Hepatology. 2019 Jun 29. doi: 10.1002/hep.30840. [Epub ahead of print]

PMID:
31254392
3.

Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson's disease.

Jones JD, Burroughs M, Apodaca M, Bunch J.

Neuropsychology. 2019 Jun 20. doi: 10.1037/neu0000577. [Epub ahead of print]

PMID:
31219297
4.

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.

Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):752-761. doi: 10.1007/s00535-019-01569-7. Epub 2019 Mar 13.

5.

Screening and Genomic Characterization of Filamentous Hemagglutinin-Deficient Bordetella pertussis.

Weigand MR, Pawloski LC, Peng Y, Ju H, Burroughs M, Cassiday PK, Davis JK, DuVall M, Johnson T, Juieng P, Knipe K, Loparev VN, Mathis MH, Rowe LA, Sheth M, Williams MM, Tondella ML.

Infect Immun. 2018 Mar 22;86(4). pii: e00869-17. doi: 10.1128/IAI.00869-17. Print 2018 Apr.

6.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.

Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb.

7.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.

J Gastroenterol. 2018 May;53(5):689. doi: 10.1007/s00535-017-1409-z.

8.

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.

J Gastroenterol. 2018 Apr;53(4):566-575. doi: 10.1007/s00535-017-1396-0. Epub 2017 Oct 20. Erratum in: J Gastroenterol. 2017 Nov 13;:.

9.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.

Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, Seike M, Takei Y, Kato K, Alves K, Burroughs M, Redman R, Pugatch DL, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Kumada H.

J Gastroenterol. 2018 Apr;53(4):557-565. doi: 10.1007/s00535-017-1391-5. Epub 2017 Sep 25.

10.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.

Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H.

Hepatology. 2018 Feb;67(2):505-513. doi: 10.1002/hep.29510. Epub 2017 Nov 24.

11.

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.

Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L Jr, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T.

J Med Virol. 2018 Jan;90(1):109-119. doi: 10.1002/jmv.24923. Epub 2017 Sep 22.

12.

Combining Precipitation and Vitrification to Control the Number of Surface Patches on Polymer Nanocolloids.

Sosa C, Lee VE, Grundy LS, Burroughs MJ, Liu R, Prud'homme RK, Priestley RD.

Langmuir. 2017 Jun 13;33(23):5835-5842. doi: 10.1021/acs.langmuir.7b01021. Epub 2017 Jun 1.

PMID:
28571320
13.

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.

Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L Jr, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H.

Adv Ther. 2017 Jun;34(6):1449-1465. doi: 10.1007/s12325-017-0506-y. Epub 2017 May 23.

PMID:
28536999
14.

The History of Bordetella pertussis Genome Evolution Includes Structural Rearrangement.

Weigand MR, Peng Y, Loparev V, Batra D, Bowden KE, Burroughs M, Cassiday PK, Davis JK, Johnson T, Juieng P, Knipe K, Mathis MH, Pruitt AM, Rowe L, Sheth M, Tondella ML, Williams MM.

J Bacteriol. 2017 Mar 28;199(8). pii: e00806-16. doi: 10.1128/JB.00806-16. Print 2017 Apr 15.

15.

Complete Genome Sequences of Bordetella pertussis Vaccine Reference Strains 134 and 10536.

Weigand MR, Peng Y, Loparev V, Batra D, Burroughs M, Johnson T, Juieng P, Rowe L, Tondella ML, Williams MM.

Genome Announc. 2016 Sep 15;4(5). pii: e00979-16. doi: 10.1128/genomeA.00979-16.

16.

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.

Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1106-13. doi: 10.1128/AAC.02606-15. Print 2016 Feb.

17.

The mitochondrial genome of the lone star tick (Amblyomma americanum).

Williams-Newkirk AJ, Burroughs M, Changayil SS, Dasch GA.

Ticks Tick Borne Dis. 2015 Sep;6(6):793-801. doi: 10.1016/j.ttbdis.2015.07.006. Epub 2015 Jul 8.

PMID:
26189992
18.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R.

Hepatology. 2015 Oct;62(4):1037-46. doi: 10.1002/hep.27972. Epub 2015 Aug 25.

19.

Agreement Between Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 Peruvian Sites.

Bazo-Alvarez JC, Quispe R, Peralta F, Poterico JA, Valle GA, Burroughs M, Pillay T, Gilman RH, Checkley W, Malaga G, Smeeth L, Bernabé-Ortiz A, Miranda JJ; PERU MIGRANT Study; CRONICAS Cohort Study Group.

Crit Pathw Cardiol. 2015 Jun;14(2):74-80. doi: 10.1097/HPC.0000000000000045.

20.

In Vitro selection of Neisseria gonorrhoeae mutants with elevated MIC values and increased resistance to cephalosporins.

Johnson SR, Grad Y, Ganakammal SR, Burroughs M, Frace M, Lipsitch M, Weil R, Trees D.

Antimicrob Agents Chemother. 2014 Nov;58(11):6986-9. doi: 10.1128/AAC.03082-14. Epub 2014 Sep 8.

21.

Draft Genome Sequence of Bacillus cereus Strain BcFL2013, a Clinical Isolate Similar to G9241.

Gee JE, Marston CK, Sammons SA, Burroughs MA, Hoffmaster AR.

Genome Announc. 2014 May 29;2(3). pii: e00469-14. doi: 10.1128/genomeA.00469-14.

22.

M3 muscarinic receptor interaction with phospholipase C β3 determines its signaling efficiency.

Kan W, Adjobo-Hermans M, Burroughs M, Faibis G, Malik S, Tall GG, Smrcka AV.

J Biol Chem. 2014 Apr 18;289(16):11206-18. doi: 10.1074/jbc.M113.538546. Epub 2014 Mar 4.

23.

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.

Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ.

J Clin Gastroenterol. 2014 May-Jun;48(5):435-43. doi: 10.1097/MCG.0000000000000000.

PMID:
24177376
24.

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.

Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9.

PMID:
24118703
25.

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH.

Value Health. 2013 Sep-Oct;16(6):973-86. doi: 10.1016/j.jval.2013.07.006.

26.

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators.

Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4.

PMID:
23924660
27.

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ.

Virology. 2013 Sep;444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029. Epub 2013 Jul 19.

28.

Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.

Hazuda DJ, Burroughs M, Howe AY, Wahl J, Venkatraman S.

Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218. Review.

PMID:
23859802
29.

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K.

Aliment Pharmacol Ther. 2013 Jul;38(1):16-27. doi: 10.1111/apt.12342. Epub 2013 May 26.

30.

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.

Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.

J Hepatol. 2013 Mar;58(3):479-87. doi: 10.1016/j.jhep.2012.11.020. Epub 2012 Nov 23.

PMID:
23183529
31.

Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK.

J Hepatol. 2013 Mar;58(3):452-9. doi: 10.1016/j.jhep.2012.11.001. Epub 2012 Nov 14.

PMID:
23159770
32.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators.

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11.

PMID:
23081753
33.

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):81-87.e4; quiz e5. doi: 10.1016/j.cgh.2012.10.006. Epub 2012 Oct 10.

PMID:
23064222
34.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-618.e5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
35.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.

Hepatology. 2012 Aug;56(2):567-75. doi: 10.1002/hep.25865. Epub 2012 Jun 29.

PMID:
22619063
36.

Direct-reversible binding of small molecules to G protein βγ subunits.

Seneviratne AM, Burroughs M, Giralt E, Smrcka AV.

Biochim Biophys Acta. 2011 Sep;1814(9):1210-8. doi: 10.1016/j.bbapap.2011.05.010. Epub 2011 May 18.

37.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

38.

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group.

Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17. Erratum in: Gastroenterology. 2013 Oct;145(4):910.

PMID:
21419770
39.

Revenue lost and found: debt buying and your bottom line.

Burroughs MJ.

Revenue-cycle Strateg. 2010 Oct;7(8):1-4. No abstract available.

PMID:
21268549
40.

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J.

J Hepatol. 2011 Feb;54(2):227-35. doi: 10.1016/j.jhep.2010.06.038. Epub 2010 Sep 15. Erratum in: J Hepatol. 2013 Oct;59(4):914.

PMID:
21056496
41.

NMR analysis of G-protein betagamma subunit complexes reveals a dynamic G(alpha)-Gbetagamma subunit interface and multiple protein recognition modes.

Smrcka AV, Kichik N, Tarragó T, Burroughs M, Park MS, Itoga NK, Stern HA, Willardson BM, Giralt E.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):639-44. doi: 10.1073/pnas.0909503107. Epub 2009 Dec 16.

42.

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group.

Gastroenterology. 2009 May;136(5):1618-28.e2. doi: 10.1053/j.gastro.2009.01.039. Epub 2009 Jan 22.

PMID:
19208349
43.

CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients.

Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL, Newell K, Rowe D, Reyes J.

Am J Transplant. 2006 Aug;6(8):1906-12.

44.

Clinical inquiries. What interventions reduce the risk of contrast nephropathy for high-risk patients?

Grossman PD, Burroughs M, Guthmann RA.

J Fam Pract. 2005 Apr;54(4):365-7. Review.

PMID:
15833230
45.

Clinical inquiries. What effect do inhaled steroids have on delaying the progression of COPD?

Hansen L, Havemann J, Burroughs M, Lo V.

J Fam Pract. 2004 Oct;53(10):835-6. Review. No abstract available.

PMID:
15469782
46.

Clinical inquiries. Does injection of steroids and lidocaine in the shoulder relieve bursitis?

Gutierrez G, Burroughs M, Poddar S.

J Fam Pract. 2004 Jun;53(6):488-92. Review. No abstract available.

PMID:
15189724
47.

Clinical inquiries. Does treatment of acne with Retin A and tetracycline cause adverse effects?

Kelly BF, Burroughs M, Mertens M.

J Fam Pract. 2004 Apr;53(4):316-8. Review. No abstract available.

PMID:
15068778
48.

The effect of a parenting education program on the use of preventive pediatric health care services among low-income, minority mothers: a randomized, controlled study.

El-Mohandes AA, Katz KS, El-Khorazaty MN, McNeely-Johnson D, Sharps PW, Jarrett MH, Rose A, White DM, Young M, Grylack L, Murray KD, Katta PS, Burroughs M, Atiyeh G, Wingrove BK, Herman AA.

Pediatrics. 2003 Jun;111(6 Pt 1):1324-32.

PMID:
12777548
49.

Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation.

Burroughs M, Sobanjo A, Florman S, Kaufman SS, Fishbein T.

Transplant Proc. 2002 May;34(3):946-7. No abstract available.

PMID:
12034253
50.

Unsuspected Toxoplasma gondii empyema in a bone marrow transplant recipient.

Dawis MA, Bottone EJ, Vlachos A, Burroughs MH.

Clin Infect Dis. 2002 May 1;34(9):e37-9. Epub 2002 Apr 3.

PMID:
11941570

Supplemental Content

Loading ...
Support Center